Back

Analysis of the PARAGON-HF study results using win ratio

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: Chronic heart failure - treatment 3 Pharmacotherapy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Wonse Kim

Seoul National University, Seoul (Korea (Republic of))

3 More presentations in this session

Presentation thumbnail
Projected lifetime benefits of sacubitril/valsartan on event-free survival in patients with HFmrEF and HFpEF in the PARAGON-HF trial
Doctor A. Foa' (Bologna, IT)
Abstract Slides Video
Presentation thumbnail
Feasibility, efficacity and safety of a fast up-titration program of heart failure treatments in real-life practice.
Miss L. Blasi (Toulouse, FR)
Abstract Slides Video
Presentation thumbnail
Real-world impact of early quadruple therapy in HFrEF: a comparative analysis of sequential vs. simultaneous approaches
Mr D. Ferreira (Lisbon, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Chronic heart failure - treatment 3

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Sacubitril/valsartan vs. valsartan initiation in patients with heart failure and EF>40% who are naive to renin-angiotensin-system inhibitors: Insights from PARAGLIDE-HF
thumbnail
Congress Presentation
Projected lifetime benefits of sacubitril/valsartan on event-free survival in patients with HFmrEF and HFpEF in the PARAGON-HF trial
thumbnail
Congress Presentation
Ivabradine improves win ratios of outcomes in HFrEF patients

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources